Hui DY, Harmony JA Interaction of plasma lipoproteins with erythrocytes. I. Alteration of erythrocyte morphology. Biochim Biophys Acta. 1979 Feb 2;550(3):407-24.
Hui DY, Noel JG, Harmony JA Binding of plasma low density lipoproteins to erythrocytes. Biochim Biophys Acta. 1981 Jun 23;664(3):513-26.
Jukema JW [The availability of only one statin is inadequate]. Ned Tijdschr Geneeskd. 2005 Dec 10;149(50):2773-4. Dutch.
Klop B, Elte JW, Cabezas MC [Cholesterol homeostasis and enterohepatic connection: new insights in cholesterol absorption]. Ned Tijdschr Geneeskd. 2011;155:A2503. Review. Dutch.
Mölgaard J, von Schenck H, Olsson AG Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia. Eur Heart J. 1988 May;9(5):541-51.
Pineda A, Cubeddu LX Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep. 2011 Feb;13(1):23-30. doi: 10.1007/s11883-010-0148-x. Review.
Poli A Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs. 2007;67 Suppl 1:3-15. Review.
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.
Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
